Nammi Therapeutics, Inc., a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC)...

Nammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round prior to the...

Nammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and...

Amgen and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticker in...

The governing Board of the California Institute for Regenerative Medicine (CIRM) funded a Phase 3 clinical trial to support the...

FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of Pancreatic Cancer. QXL...

FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of multiple myeloma. QXL...

LOS ANGELES, April 9, 2021 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi), an LA- based immunotherapy company, announces its first two...

Veteran drug developer David Stover decided to start his own firm the day Astellas Pharma Inc. shuttered its Santa Monica-based Agensys...